Stay updated on MBG453 Combo in IPSS-R MDS Clinical Trial
Sign up to get notified when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.

Latest updates to the MBG453 Combo in IPSS-R MDS Clinical Trial page
- CheckyesterdayChange DetectedVersion v3.3.4 was added (2026-01-13) with new core content sections Adverse Events, Participant Flow, References, Contacts/Locations, and Study Status; the older Revision: v3.3.3 entry from 2025-11-24 was removed.SummaryDifference0.4%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision: v3.3.3 was added to the page history and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision updated in the footer from v3.3.1 to v3.3.2. This is a minor site version update and does not affect the study information displayed.SummaryDifference0.0%

- Check52 days agoChange DetectedIn December 2023, Novartis terminated the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) failed to meet primary objectives. The termination was not due to safety concerns, and the 2025 revision added new sections such as Limitations and Caveats, Adverse Events, Outcome Measures, Baseline Characteristics, and Participant Flow.SummaryDifference0.6%

- Check59 days agoChange DetectedRemoval of a government funding/status notice from the page; no trial record content or navigation is affected.SummaryDifference0.3%

- Check73 days agoChange DetectedThe two screenshots display the same record history page with only cosmetic differences and no changes to the study data or status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to MBG453 Combo in IPSS-R MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.